Last reviewed · How we verify

NCT06851494: LinneaSafe30

Safety and Efficacy of Linnea Safe PMMA 30% Use for Gluteal Augmentation.

Not yet recruiting NA Last updated 4 March 2025
What this trial tests

NA trial testing PMMA in Gluteal Augmentation in 137 participants. Not yet recruiting.

Timeline
1 November 2025
Primary endpoint
1 November 2026
1 November 2026

Quick facts

Lead sponsorLEBON PRODUTOS QUIMICOS E FARMACEUTICOS LTDA.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment137
Start date1 November 2025
Primary completion1 November 2026
Estimated completion1 November 2026

Drugs / interventions tested

Conditions studied

Sponsor

LEBON PRODUTOS QUIMICOS E FARMACEUTICOS LTDA.

Who can join

18 and older, any sex, with Gluteal Augmentation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pre-market, interventional, single-arm study aims to evaluate the safety and efficacy of LinneaSafe 30% polymethylmethacrylate (PMMA) for gluteal augmentation. The study will include 119 patients, with a total recruitment of 137 to account for a 15% drop-out rate. Eligible participants are men and women over 18 years old who express interest and are deemed suitable for the procedure. The primary safety outcome is the incidence of adverse events, while the primary efficacy outcome is patient satisfaction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PMMA

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06851494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing